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Abstract
Docetaxel is a semisynthetic cytostatic drug that belongs to the family of taxoids. Docetaxel inhibits normal interphase and mitotic 
cellular function, causing cell death.
Docetaxel is indicated for the treatment of breast, lung and prostate cancers, head and neck cancer and gastric adenocarcinoma.
Interstitial pneumonitis is an uncommon side effect of docetaxel. We report a case of docetaxel induced interstitial lung disease 
(ILD) in a patient with breast cancer.
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Introduction
Docetaxel is a semisynthetic derivative of 
10-deacetylbaccatin III obtained from the nee-
dles of yew species, such as the European yew 
(Taxus baccata). Along with paclitaxel it belongs 
to the taxoids, which have been introduced into 
clinical practice in the 90’s of the past century. 
Docetaxel is commonly used in monotherapy 
and in combinations with doxorubicin and cy-
clophosphamide in the adjunctive treatment of 
breast cancer with metastases to lymph nodes, in 
the treatment of locally advanced breast cancer, 
advanced non-small-cell lung cancer (NSCLC), 
prostate cancer, stomach adenocarcinoma, head 
and neck cancer. It was approved for use in Eu-
ropean Union in 1995.
Docetaxel acts mainly by distorting micro-
tubules. The spindle fibres formation is thus 
impaired and consequently mitosis and further 
proliferation of cells is inhibited. Taxoids also 
influence the microtubule associated proteins 
(MAPs) and the proteins of the mitotic cycle. They 
induce apoptosis, inhibit angiogenesis, cell mobil-
ity and synthesis of metalloproteinases. All these 
actions add up to their antineoplastic potential.
Neutropenia is the main toxicity of docetax-
el. Also anaemia, nausea, vomiting, loss of hair, 
stomatitis, diarrhoea and malaise are frequently 
reported [1−3].
Infusion-related reactions (IRRs) often occur 
during taxoid therapy. IRRs are hypersensitiv-
ity reactions caused by degranulation of mast 
cells. They develop shortly after administration 
of the cytostatic drugs and manifest with cough, 
bronchospasm, dyspnoea, fever and falls in 
blood pressure [2]. The toxicity of docetaxel may 
be greater if infused in combination with other 
chemotherapeutic agents [4−7].
Interstitial lung disease (ILD) is a rare side 
effect of docetaxel therapy [1, 2, 8−12].
We present a patient with breast cancer 
treated with three cycles of docetaxel in combi-
nation with doxorubicin and cyclophosphamide 
who developed ILD mimicking hypersensitivity 
pneumonitis (HP).
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Case report
A 61-year old, never-smoking, female with 
arterial hypertension and hyperthyroidism man-
aged with thiamazole and propranolol, was ad-
mitted to the emergency unit of our Institution on 
15th April 2013 complaining of dyspnoea at rest 
that aggravated within past few days. Her past 
medical history revealed an episode of deep vein 
thrombosis of the left lower limb in 2010, which 
had been treated with a low molecular weight 
heparin (LMWH) for six months.
In January 2013 she underwent a sparing 
operation of left breast cancer with lymphadenec-
tomy. Subsequently she has been scheduled for 
chemotherapy that comprised docetaxel, doxoru-
bicin and cyclophosphamide. The third chemo-
therapy cycle was given on 20th March 2013 and 
on the next day she developed fever of 38ºC with 
dyspnoea and non-productive cough. She was 
initially treated as outpatient with amoxicillin 
and cefuroxime, with no effect.
On admission the patient was in a moderate 
general condition with tachycardia of 120/min 
and dyspnoea at rest. Auscultation revealed mild 
attenuation of vesicular murmur. There were no 
crackles. The patient complained of left-sided chest 
pain. There was no haemoptysis. She had been 
taking LMWH prophylactically at a dose of 40 mg 
a day subcutaneously. Chest X-ray taken four days 
prior to admission showed interstitial opacities 
indicative of inflammation in the lower field of the 
left lung, unfortunately the picture was unavailable.
Analysis of capillary blood gases showed 
oxygen saturation of 95%, pO2 — 70.4 mm Hg, 
pCO2 — 35.4 mm Hg, pH — 7.47, fibrin degra-
dation products D-dimer — 1830 µg/l (reference 
range 68−494 µg/l). The C-reactive protein (CRP) 
concentration was 25 mg/l (reference < 10 mg/l). 
The blood count was normal.
Computed tomography (CT) of the chest with 
iodine contrast agent administration was per-
formed. The dose of thiamazol was thus temporari-
ly increased. No thrombi in the pulmonary arteries 
were found. However considerable variations in 
parenchymal density were notable. The overall 
picture was indicative of ILD with ground-glass 
opacities most prominent in the upper fields of 
both lungs. There was no air-trap upon expiration. 
Besides, small peribronchial opacifications were 
noted in the third segment of the left lung (Figs 
1A, B). In the opinion of the radiologist the picture 
could have been associated with drug toxicity.
The patient recalled no contact with typical 
allergens. Also, precipitin reactions against an-
tigens of thermophilic actinomycetes and farm 
bird faeces were negative. The ivestigation of 
ventilatory mechanics showed normal total lung 
capacity and vital capacity, and the airflow param-
eters remained within the reference range. The 
diffusing capacity for carbon monoxide (DLCO) 
was not evaluated due to poor compliance.
Due to poor clinical status of the patient, 
characteristic picture of CT findings, broncho-
alvelar lavage (BAL) and transbronchial lung 
biopsy was considered unsafe and unnecessary.
Figure 1. Computed tomography scan
A B
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Taking into account the antineoplastic treat-
ment that included pneumotoxic docetaxel and 
the radiological findings indicative of ILD we 
reached the decision to apply corticosteroids 
at an initial dosage of 0.5 mg/kg of body mass 
a day. Prednisone at a dose of 50 mg/day was 
commenced along with ciprofloxacin due to the 
observed inflammatory infiltrates. The general 
condition of the patient improved.
The patient was followed at the end of May 
2013, one month after corticosteroid treatment 
initiation. She declared substantial improvement 
in general feeling and no dyspnoea. A high-resolu-
tion CT scan (HRCT) revealed absolute regression 
of infiltrates. There were no ground-glass opac-
ities and no nodules, previously seen in the left 
third segment (Fig. 2). Spirometry was inconclu-
sive due to poor compliance. The capillary blood 
gas analysis revealed oxygen saturation of 96%, 
pO2 — 86 mm Hg, pCO2 — 33 mm Hg. During the 
6-minutes walk test (6MWT) the patient walked 
the distance of 370 m with initial oxygen satu-
ration of 98% and of 90% at the end of the test.
Due to the regression of radiological findings 
we decided to reduce the dosage of prednisone 
to 40 mg/day.
The patient was admitted again in July 2013. At 
that time she remained in good general condition. 
The blood gas analysis was normal, the distance in 
6MWT was 380 m, during which oxygen saturation 
remained stable. The chest X-ray was normal.
We decided to further gradually reduce the 
dose of prednisone on outpatient basis without 
scheduled follow-up in our Institution.
Discussion
Adverse drug reactions are increasingly often 
seen in the respiratory system. They total to about 
7% of all adverse drug reactions [2, 13].
Among the inadvertent reactions in res-
piratory system bronchospasm, bronchiolitis, 
pleural effusion, mediastinal lymphadenopathy, 
vascular reactions of pulmonary hypertension 
and thromboembolism, and hypersensitivity re-
actions are encountered. Interstitial lesions are 
a specific manifestation of reaction to antineo-
plastic drugs. These occur more often in the case 
of combined cytotoxic treatments, radiotherapy, 
long-term oxygen therapy, renal insufficiency, con-
comitant lung disease and advanced age [2, 13].
Among interstitial lung diseases: HP, usual in-
terstitial pneumonia (UIP), organizing pneumonia 
(OP), desquamative interstitial pneumonia(DIP), 
diffuse alveolar damage (DAD) , diffuse alveolar 
haemorrhage (DAH) and pulmonary vasculitis can 
be discerned [3, 4, 13, 14]. According to the avail-
able literature the most common form of docetax-
el-induced lung toxicity is HP [2, 7, 11, 12].
Docetaxel is a potent antitumor, yet toxic drug. 
It may cause pulmonary injury through multiple, 
currently poorly understood mechanisms. Various 
reactions have been described in the course of 
docetaxel treatment: anaphylactic hypersensi-
tivity and infusion related reactions. The doceta-
xel-induced lung toxicity in the cases that have 
been reported usually occurred after the second to 
fourth course of chemotherapy, and was usually 
relieved with corticosteroid therapy. Therefore, 
the involvement of a cytotoxic T-cell-mediated 
mechanism is very likely [1, 2, 4, 8, 15].
One of the earlier and thus better-explored 
toxoids — paclitaxel — induces acute bron-
chospasm and anaphylactic reactions in 30% 
of patients not pre-treated with antihistamine 
drugs or corticosteroids. These reactions result 
probably from basophil injury and mast cells 
degranulation. Besides acute cough, fever and 
interstitial pulmonary infiltrates have been re-
ported [2, 3, 13].
Cytotoxic drugs may distort the oxida-
tion-reduction, immunological, metabolic, and 
neuroregulatory balances as well as reparative 
processes. They also impair the neutralization 
of free radicals by antioxidants, which results 
in pulmonary injury, inflammation and fibro-
sis. By indirect alterations in inflammatory 
processes they enhance the inflow of inflam-
matory cells and the destruction of pulmonary 
parenchyma [3].
Figure 2. High resolution computed tomography
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Histopathological examination in cytostatic 
induced ILD often reveals atypical distorted type 
II pneumocytes with large hiperchromatic nuclei. 
In late hypersensitivity reactions infiltrates of 
atypical granulomas are common [3, 14].
Interstitial pneumonia may develop within 
days or weeks following administration of docetax-
el. Initially the symptoms may be non-specific. 
There may be cough, fever, acute bronchiolitis, 
dyspnoea initially on exertion then at rest, or sud-
den dyspnoea as in non-cardiogenic pulmonary 
oedema [3, 15]. Respiratory failure may develop, 
being at times lethal [8]. 
Radiological examination shows variable 
levels of parenchyma involvement ranging from 
discreet, hardly discernible in conventional chest 
X-rays, through ground-glass opacities, up to 
massive infiltrates [3, 13, 14].
HRCT may reveal diffused nodo-reticular 
infiltrates, signs of alveolar flooding as in non-car-
diogenic pulmonary oedema, alveolar haemor-
rhages or eosinophilic pneumonia. In acute HP 
radiological signs include localized or diffused 
infiltrates. In chronic states these infiltrates be-
come nodular or reticulo-nodular. At that stage 
they tend to be more pronounced in the superior 
lobes. Typically seen in HRCT are the mosaic-like 
ground glass opacities [3, 13, 14].
According to Wang four patients with ad-
vanced NSCLC treated with docetaxel developed 
life-threatening HP requiring mechanical ventila-
tion. The first patient developed symptoms five 
days following the first dose of docetaxel, and 
the remainder between the second and the sixth 
cycle of chemotherapy. The diagnosis was estab-
lished based on the radiological findings after 
excluding connective tissue diseases, infection 
and metastases. The patients were treated with 
corticosteroids. Three out of four experienced 
partial remission, but eventually suffered from 
sustained interstitial disease and infective com-
plications [11].
Grande et al. described a case of ILD induced 
by docetaxel following treatment of NSCLC. It 
resulted from type I and IV drug-related hyper-
sensitivity reactions. In general, both clinical and 
radiological signs tend to be non-specific and the 
final diagnosis is pronounced after exclusion of 
other conditions. The disease is usually cured 
with corticosteroids, yet occasional progression 
to pulmonary fibrosis is possible [12].
Gurram et al. described a similar case to 
ours. A patient treated for advanced breast cancer 
developed HP following three cycles of docetaxel. 
It led to respiratory failure resulting in death, 
despite intensive corticosteroid therapy [8].
Ochoa reported interstitial pneumonia with 
fibrosis in a patient taking adjuvant chemo-
therapy comprising docetaxel and cyclophos-
phamide because of advanced breast cancer. 
Within two weeks following the third cycle of 
chemotherapy the patient developed rapidly 
progressing dyspnoea along with non-pro -
ductive cough and mild hypoxemia. Chest CT 
scan showed subpleural lesions. Lung biopsy 
revealed subacute interstitial pneumonia. The 
patient improved quickly upon introduction of 
corticosteroids [7].
Docetaxel needs to be discontinued in all 
cases. The clinical, pathologic, and radiographic 
data supported pulmonary toxicity caused by 
a hypersensitivity reaction to docetaxel as the 
most likely etiology. The authors recommend, 
that any patient who develops a taxane- induced 
pulmonary toxic reaction, must not be rechal-
lenged or treated with another agent of the same 
class [15].
Conclusion
Interstitial pneumonia is on occasion related 
to side effects of docetaxel treatment [3, 9, 10]. 
According to the available literature the most 
common form is HP [7, 8, 11, 12].
We presented a case of a patient who follow-
ing three cycles of chemotherapy, given for breast 
cancer, developed symptoms of HP: fever, dysp-
noea, dry cough and typical radiological signs.
The diagnosis was eventually established 
based on history, clinical signs and HRCT find-
ings. We excluded pulmonary embolism and me-
tastases to the respiratory system. Unfortunately 
it was not possible to fully evaluate ventilatory 
mechanics and DLCO due to poor compliance, 
which led to non-repeatable results.
Chemotherapy was terminated in our patient 
after three cycles out of planned six. The patient 
was then referred to radiotherapy. The use of 
corticosteroids led to full remission of intersti-
tial lesions thus preventing respiratory failure 
and lung fibrosis, which in turn gave the patient 
an opportunity to pursue further antineoplas-
tic treatment.
Oncologists should remember that patients 
have contraindication for continuation of che-
miotherapy.
Familiarity with adverse effects of docetax-
el, including possible reactions within the 
respiratory system is very important. The use 
of appropriate pre-treatment, comprising anti-
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histaminic drugs and corticosteroids may pre-
vent complications. Appropriate recognition of 
simultaneously occurring symptoms, such as: 
impending dyspnoea, dry cough and fever in 
the context of possibly occurring ILD enables 
proper scheduling of diagnostics, early cyto-
static withdrawal and appropriate corticoster-
oid administration.
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